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Purpose: To elucidate the effects of tumor necrosis factor (TNF)-a on the expression of inducible nitric
oxide synthase (iNOS) in retinal pigment epithelial cells in vitro.
Methods: ARPE-19 cell lines were cultured with TNF-a stimulation, and then treated with proteasome
inhibitors (MG132 or lactacystin) for 30 minutes. The expression of iNOS was determined by RT-PCR and
Western blot. The expression of nitric oxide (NO) was determined by an enzyme-linked immunosorbent
assay. The interaction of nuclear factor kappa-B (NF-kB) activation and iNOS induction was assessed by
electrophoretic mobility shift assay.
Results: The expression of iNOS in ARPE-19 was induced by TNF-a in a dose-dependent manner. Upre-
gulation of iNOS resulted in increased production of NO. iNOS induced by TNF-a could be inhibited by
MG-132 and lactacystin. Supershift assay revealed that NF-kB activation was responsible for iNOS
induction.
Conclusion: TNF-a could induce iNOS expression and NO production in RPE cells, at least in part, via an
NF-kB signal pathway.
Copyright  2011, The Ophthalmologic Society of Taiwan. Published by Elsevier Taiwan LLC. All rights
reserved.1. Introduction
Nitric oxide (NO) is an inorganic, gaseous molecule which is
synthesized in the retina by vascular, neuronal, and glial cells.1,2
NO is synthesized by nitric oxide synthase (NOS). There are
three forms of NOS: endothelial NOS (eNOS), neuronal NOS
(nNOS), and inducible NOS (iNOS).3,4 NO constitutively formed
by eNOS and nNOS plays important roles in the regulation of
physiologic functions, whereas NO produced by iNOS in excessive
amounts leads to cytotoxicity, neurodegeneration, apoptotic cell
death, and circulatory failure.5e8 In the eyes, excess NO has been
implicated in the pathogenesis of various disorders, including
glaucoma, uveitis, and ischemic retinopathy9e11 iNOS was shown
to be induced in vitro in retinal pigment epithelial (RPE) cells
and retinal Müller cells by various immuno-stimuli, such as
interferon-g (IFNg), tumor necrosis factor-alpha (TNF)-a, and
lipopolysaccharide (LPS).12e14almology, National Taiwan
ad, Taipei, Taiwan.
g).
e Ophthalmologic Society of TaiwaTNF-a participates in the pathogenesis of several inﬂammatory,
neovascular, and degenerative ocular diseases.15,16 Recent evidence
has suggested that TNF-a may be an crucial player in the complex
network of inﬂammation, linking angiogenesis and inﬂammation.17
The biologic activities of TNF-a are performed through the TNF-a
receptor. The TNF-a receptor was detected in the photoreceptors,
RPE, and Müller cells; these structures can also express iNOS,18e20
which implies that TNF-a may be involved in the regulation of
iNOS expression in the retina. However, the exact mechanisms of
TNF-a-induced iNOS expression in RPE cells has been unknown.
Nuclear factor kappa B (NF-kB) plays an important role in
controlling inﬂammatory and immune responses.21 In unstimu-
lated cells, NF-kB is maintained in the cytosol as a heterodimer in
complex with its inhibitory protein, IkB. When cells are stimulated,
IkB is phosphorylated and degradated. This phosphorylation
dissociates NF-kB from IkB and allows NF-kB to translocate to the
nucleus, where it activates its target genes including iNOS.22, 23
However, in RPE cells, the signaling mechanisms inducing iNOS
by TNF-a association with NF-kB activation are not completely
deﬁned. Thus, in this study, we examined in vitro iNOS expression
in ARPE-19 cells by the proinﬂammatory cytokine TNF-a, stimula-
tion. Using NF-kB inhibitors, MG-132, and lactacystin, we sought ton. Published by Elsevier Taiwan LLC. All rights reserved.
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RPE cells.
2. Methods
2.1. Cell culture
ARPE-19 cells were obtained from Bioresource Collection and
Research (Hsinchu, Taiwan). The ARPE-19 cell line is an established
cell line that has been shown to express many of the characteristics
of RPE cells in culture. ARPE-19 cells were incubated in Dulbecco’s
modiﬁed Eagle’s medium (DMEM, Biochrome KG, Berlin, Germany)
supplemented with 10% (v/v) fetal bovine serum, 500 U/mL peni-
cillin, and 500 mg/mL streptomycin. All cells were maintained at
37C in a humidiﬁed 5% CO2, 95% air incubator.
2.2. TNF-a, MG-132 and lactacystin treatment
ARPE-19 cells were seeded at a density of 105 cells/well in six-
well plates, and grown to conﬂuence. To investigate the dose
response of TNF-a on iNOS mRNA expression, ARPE-19 cells were
exposed for 4 hours to 10, 50, 100, and 200 ng/mL TNF-a, and
medium alone (control). For NF-kB experiments, ARPE-19 cells
were pretreated with 200 mM MG-132 (Calbiochem, Darmstadt,
Germany) or 50 mM lactacystin (Cayman, Ann Arbor, MI, USA) for
1 hour and then incubated in new medium containing TNF-a
200 ng/mL for 4 hours.
2.3. Reverse transcription-polymerase chain reaction
Total RNA was extracted from ARPE-19 cells with Trizol reagent
(Invitrogen, Carlsbad, CA, USA). Extracted RNA (1 mg) was reverse
transcribed to cDNA using 80 U Moloney murine leukemia virus
reverse transcriptase (MMLV-RT; Invitrogen) for 45 minutes at
37C. Polymerase chain reaction (PCR) was performed in a reaction
mixture of 50 mL containing 5 mL cDNA, 1 mL of sense and antisense
primer, 200 mM of dNTPs, 5 mL 10 Tag polymerase buffer, and 1.25
U Tag polymerase (Promega, Madison, WI, USA). Primer sequence
for iNOS was forward primer 50-ACAGGAGGGGTTAAAGCTGC-30;
reverse primer 50-GCAGCTTTAACCCCTCCTGT-30. Cycling parame-
ters for iNOS ampliﬁcation were as follows: 94C for 60 seconds,
55C for 60 seconds, and 72C for 120 seconds. At the end of
ampliﬁcation, the reaction mixture was heated for 10 minutes at
72C and then cooled to 4C. A 10-mL sample of each PCR product
was electrophoresed on 2% agarose gel containing ethidium
bromide (Sigma, St Louis, MO, USA) in TAE buffer. The electropho-
retic bands were documented and analyzed using an image
analyzer (Digital 1D Science; Eastman Kodak, Rochester, NY, USA).
GAPDH was used as a house keeping gene control.
2.4. Western blot analysis
ARPE-19 cells were washed with ice-cold phosphate-buffered
saline (PBS) and lysed in 1 mL RIPA lysis buffer (Upstates, Lake
Placid, NY, USA). Cell lysates were mixed 1:1 with Laemmli’s
sample buffer (Bio-Rad Laboratory, CA, USA) and boiled for 5
minutes. An equal amount of proteins were subjected to 10%
sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-
PAGE) (Piscataway, NJ, USA). Separated proteins were electro-
phoretically transferred from the gel to a PVDF membrane
(Amersham and Pharmacia Biotech). The membrane was blocked
with 5% milk in Tris-buffered saline with 0.1% Tween 20 for 1 hour
at room temperature, and probed with anti-human fractalkine
antibody (R&D Systems, Minneapolis, MN, USA) at 4C overnight.
After washing, the blots were incubated with secondary antibodycoupled with horseradish peroxidase (Amersham and Pharmacia
Biotech) for 1 hour at room temperature. Antibody-antigen
complexes were then detected using enhanced chem-
iluminescence detection system (ECL, Amersham and Pharmacia
Biotech) according to the manufacturer’s instructions.2.5. Measuring Nitric oxide production by ARPE-19 cells
Nitrite concentrationwas determined in the supernatant of cells
and used as an index of NO synthesis. Nitrite was quantiﬁed
colorimetrically after its reaction with Griess reagent using sodium
nitrite as a standard. For measuring the nitrite concentration in cell
medium, an equal volume of Griess reagent was added to the cell
medium (0.5 mL), and the absorbance of themixturewasmeasured
at 580 nm using a Beckman DU 640 spectrophotometer (Beckman
Instruments, Inc., Fullerton, CA, USA).2.6. Electrophoretic mobility shift assay
ARPE-19 cells were harvested and washed, and nuclear protein
were extracted with NE-PER nuclear and cytoplasmic extraction
reagents (Pierce Chemical Co., IL, USA) according to the manufac-
turer’s instructions. Equal amounts (10 mg) of nuclear protein
extracts were subjected to a test for NF-kB protein/DNA binding
using LightShift chemiluminescent electrophoretic mobility shift
assay (EMSA kit, Pierce, Rockford, IL, USA) with a biotin end-labeled
NF-kB oligonucleotide (50-AGTTGAGGGGACTTTCCCAGG-30) (Prom-
ega). Brieﬂy, nuclear extracts were incubated in binding buffer with
biotin end-labeled NF-kB oligonucleotide for 15 minutes at 4C to
allow DNA/protein binding. Speciﬁcity was determined by the
addition of a 100-fold excess of unlabeled double-stranded NF-kB.
To conﬁrm the identity of NF-kB binding, supershift experiments
were performed using anti-NF-kB p65 (Rel A; Rabbit) antibody
(Rockland, Gilbertsville, PA, USA). The DNA/protein complexes were
then resolved by a 6% native polyacrylamide gel electrophoresis in
0.5  Tris-borate-EDTA buffer and transferred to a Hybond-Nþ
membrane (Amershan and Pharmacia Biotech). The biotin end-
labeled DNA was detected using streptavidin-horseradish peroxi-
dase conjugate, and a chemiluminescent substrate.3. Results
3.1. TNF-a induced iNOS mRNA expression in ARPE-19 cells
To determine whether iNOS mRNA expression could be stimu-
lated by TNF-a, we investigated iNOS mRNA expression in ARPE-19
cells stimulated with TNF-a for 4 hours. Treatment of ARPE-19 cells
with TNF-a increased the expression of iNOS mRNA in a dose-
dependent manner from concentration of TNF-a 0 to 100 ng/mL
(Fig. 1). The effect of TNF-a-induced iNOS mRNA expression was
decreased at a concentration of 200 ng/mL, when compared with
a concentration of 100 ng/mL.3.2. TNF-a induced iNOS protein expression in ARPE-19 cells
To further determine whether increased iNOS mRNA expression
induced by TNF-a resulted in enhanced protein expression, ARPE-
19 cells were treated with TNF-a for 4 hours, and iNOS protein
expression was determined by Western blot analysis. The trends
of iNOS protein expression were similar to that of iNOS mRNA
expression. Exposure of ARPE-19 cells to TNF-a resulted in
increased iNOS protein expression in a dose-dependent manner
(Fig. 2).
Fig. 2. TNF-a induced iNOS protein expression in ARPE-19 cells. The expression of
iNOS protein in ARPE-19 induced by TNF-a was examined by Western blot analysis.
ARPE-19 cells were stimulated with various concentrations of TNF-a (10, 50, 100, and
200 ng/mL) for 4 hours, and the expression of iNOS protein was quantiﬁed as
a percentage of GAPDH.
Fig. 3. TNF-aeinduced nitric oxide expression in ARPE-19 cells. We analyzed NO
expression in ARPE-19 cells by enzyme-linked immunosorbent assay (ELISA) kit. ARPE-
19 cells were stimulated with various concentrations of TNF-a (10, 50, 100, and 100 ng/
mL) for 4 hours, and subsequently the expression of NO was examined.
Fig. 1. TNF-aeinduced iNOS mRNA expression in ARPE-19 cells. The upregulation of
iNOS mRNA expressions in ARPE-19 induced by TNF-a was measured by reverse
transcriptase-polymerase chain reaction (RT-PCR). ARPE-19 cells were stimulated with
various concentrations of TNF-a (10, 50, 100, and 200 ng/mL) for 4 hours, and the
expression of iNOS mRNA was quantiﬁed as a percentage of GAPDH.
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We investigated whether exposure of ARPE-19 cells to TNF-a
could increase NO expression. Treatment for 4 hours with TNF-a
also resulted in increased NO concentrations in a dose-dependent
manner (Fig. 3).
3.4. MG-132 and lactacystin inhibited TNF-a induced iNOS mRNA
and protein expression in ARPE-19 cells
We next investigated whether TNF-aeinduced iNOS expression
is NF-kB dependent in RPE cells. For this purpose, ARPE-19 cells
were pre-incubated for 1 hour with MG-132 (200 mM), lactacystin
(50 mM), or medium alone and subsequently cultured in new
medium containing 100 ng/mLTNF-a for 4 hours. As shown in Fig. 4,
TNF-a-induced iNOS mRNA expression in ARPE-19 cells wasFig. 4. MG-132 and lactacystin inhibited TNF-a induced iNOS mRNA expression in
ARPE-19 cells. RT-PCR analysis of TNF-a induced iNOS mRNA expression in ARPE-19
cells in the presence of MG-132 or lactacystin. ARPE-19 cells were pretreated with
MG-132 (200uM), lactacystin (50uM), or medium alone for 1 hour, and then stimu-
lated with TNF-a (100 ng/mL) for 4 hours. Induction of iNOS mRNA by TNF-a was
inhibited by MG-132 or lactacystin. TþM represents TNF-a þ MG-132; TþL represents
TNF-a þ lactacystin.
Fig. 5. Western blotting was performed to determine MG-132 and lactacystin effects
on TNF-a induced expression of iNOS protein in ARPE-19 cells. ARPE-19 cells were
pretreated with MG-132 (200uM), lactacystin (50uM), or medium alone for 1 hour, and
then stimulated with TNF-a (100 ng/mL) for 4 hours. Induction of iNOS protein by TNF-
a was inhibited by MG-132 or lactacystin. TþM represents TNF-a þ MG-132; TþL
represents TNF-a þ lactacystin.
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blot analysis of iNOS also showed that TNF-a-induced iNOS protein
expression in ARPE-19 cells was almost totally abolished byMG-132
or lactacystin (Fig. 5).
3.5. Detection of nuclear NF-kB complex in ARPE-19 cells stimulated
with TNF-a by EMSA
TNF-a induced an increase in nuclear NF-kB complex. The
addition of MG-132 and lactacystin inhibited NF-kB activities. The
speciﬁcity of this reaction was conﬁrmed by the addition of a 100-
fold excess of unlabeled oligonucleotides, which eliminated the
reactive band. The addition of antibodies directed against the 65-
kDa subunit (p65) of NF-kB induced a supershift of the binding
complexes (Fig. 6).Fig. 6. Inhibitory effects of MG-132 and lactacystin on NF-kB activities induced by TNF-
a in ARPE-19 cells was detected by electrophoretic mobility shift assay. The cultured
ARPE-19 cells were pretreated for 1 hour with MG-132 (200 mM), lactacystin (50 mM),
or medium alone, and subsequently maintained in TNF-a (100 ng/mL) for 4 hours.
Nuclear extracts (10 mg) were obtained and incubated with biotin end-labeled NF-kB
oligonucleotide. To test for speciﬁcity of NF-kB binding, we carried out supershift
analysis with anti-p65 antibody, and competition experiments with a 100-fold excess
of unlabeled oligonucleotides.4. Discussion
In this study, we demonstrated that exposure of ARPE-19 toTNF-
a resulted in a dose-dependent increase inmRNA and protein levels
of iNOS. The upregulated iNOS may subsequently enhance the
production of NO, and known potent angiogenic and inﬂammatory
modulators that might contribute to inﬂammatory and angiogenic
processes. Moreover, our results revealed that TNF-a-induced iNOS
expression in ARPE-19 cells is mediated at least in part via activa-
tion of an NF-kB pathway.
TNF-a-induced iNOS expression has been demonstrated in
a variety of cell types. Nakaizumi et al, showed that exposure to
TNF-a increased the activation of NF-kB and the expression of iNOS
in retinal ganglion cell (RGC)-5 line.24 Shin et al, showed that TNF-a
increases iNOS expression and leads to NO production in murine
macrophages.25 Our study extended the scope and showed
TNF-a-induced iNOS expression in RPE cells. The expression of
TNF-a is elevated in ischemia-induced retinal injuries, inﬂamma-
tion, diabetic retinopathy, and age-related macular degeneration
(AMD).26,27 TNF-a is a pivotal inﬂammatory mediator that activates
leukocytes and promotes inﬂammatory cell migration. Moreover,
TNF-a can induce cell apoptosis, differentiation, and activation. In
this study, we found that TNF-a stimulated ARPE-19 cells to secrete
NO. In RPE, NO contributes to the function of phagocytosis of rod
outer segments and regulation of vascular endothelial growth
factor gene expression. The secretion of NO by RPE cells may
continue to promote and amplify the inﬂammatory and angiogentic
responses.
Overexpression of iNOS appears to be a consequence of
increased transcription. Several studies demonstrate that the
promoter region of iNOS contain NF-kB binding sites.28 Transcrip-
tion factors NF-kB has been shown to control the transcription of
iNOS genes in many cell types.29 In this study, we found that TNF-a
increased DNA binding activity of NF-kB in RPE cells. Furthermore,
induction of iNOS mRNA expression by TNF-a was signiﬁcantly
inhibited by two NF-kB speciﬁc proteasomal inhibitors, MG-132,
and lactacystin, which indicates that activation of NF-kB was
involved in TNF-a-induced expression of iNOS. Several reports
demonstrated that TNF-a can induce iNOS expression through
activation of an NF-kB signal pathway.30 Consistent with the ﬁnd-
ings of other groups, we found TNF-a-induced iNOS expression is,
at least in part, via an NF-kB dependent pathway. The nuclear
transcription factor NF-kB is a pivotal regulator of many important
genes including multiple inﬂammatory chemokines. There are
multiple factor binding sites in the iNOS gene promoter region and
kB binding sites that bind with NF-kB are the most important.31
From this point of view, NF-kB acts as a common regulator for
various proinﬂammatory cytokines and may be a drug target for
therapeutic applications, especially in ocular inﬂammatory and
angiogenic diseases.
In conclusion, we report here that TNF-a-induced expression of
iNOS and NO release in RPE cells were mediated through activation
NF–kB. Understanding the signaling pathways of TNF-a in RPE cells
may have signiﬁcant therapeutic implications in developing a novel
strategy against ocular inﬂammatory and angiogenic diseases.References
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